首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   358篇
  免费   14篇
  国内免费   1篇
耳鼻咽喉   1篇
儿科学   7篇
基础医学   22篇
临床医学   78篇
内科学   87篇
神经病学   7篇
特种医学   3篇
外科学   24篇
综合类   7篇
预防医学   39篇
眼科学   1篇
药学   27篇
中国医学   2篇
肿瘤学   68篇
  2023年   2篇
  2022年   9篇
  2021年   11篇
  2020年   2篇
  2019年   4篇
  2018年   4篇
  2017年   6篇
  2016年   5篇
  2015年   14篇
  2014年   8篇
  2013年   12篇
  2012年   22篇
  2011年   17篇
  2010年   20篇
  2009年   16篇
  2008年   29篇
  2007年   32篇
  2006年   31篇
  2005年   31篇
  2004年   27篇
  2003年   16篇
  2002年   12篇
  2001年   10篇
  2000年   9篇
  1999年   4篇
  1998年   2篇
  1997年   1篇
  1994年   1篇
  1992年   3篇
  1991年   2篇
  1990年   2篇
  1989年   2篇
  1988年   2篇
  1987年   2篇
  1986年   2篇
  1985年   1篇
排序方式: 共有373条查询结果,搜索用时 0 毫秒
371.
372.
Variation of a short (TA)(n) repeat sequence (rs8175347) covering the TATA box of UGT1A1 (UDP-glucuronosyltransferase1A1) is associated with hyperbilirubinaemia (Gilbert's syndrome) and adverse drug reactions, and is used for dosage advice for irinotecan. Several reports indicate that the low-activity (risk) alleles ((TA)(7) and (TA)(8) )) are very frequent in Africans but the patterns of association with other variants in the UGT1A gene complex that may modulate these responses are not well known. rs8175347 and two other clinically relevant UGT1A variants (rs11692021 and rs10929302) were assayed in 2616 people from Europe and Africa. Low-activity (TA)(n) alleles frequencies were highest in equatorial Africa, (TA)(7,) being the most common in Cameroon, Ghana, southern Sudan, and in Ethiopian Anuak. Haplotypic diversity was also greatest in equatorial Africa, but in Ethiopia was very variable across ethnic groups. Resequencing of the promoter of a sample subset revealed no novel variations, but rs34547608 and rs887829 were typed and shown to be tightly associated with (TA)(n) . Our results illustrate the need for investigation of the effect of UGT1A variants other than (TA)(n) on the risk of irinotecan toxicity, as well as hyperbilirubinaemia due to hemolytic anaemia or human immunodeficiency virus protease inhibitors, so that appropriate pharmacogenetic advice can be given.  相似文献   
373.
BACKGROUND: Though there are few studies, mainly on children, very little is known about its occurrence in Ethiopian adults. OBJECTIVE: To assess the clinical presentations, clinical findings, operative findings (including types and identification of specific causes), modes of treatment, and postoperative outcome in adult patients operated for intussusception. METHODS: A retrospective review of adolescent and adult patients' record with intra operative diagnosis of intussusception over a period of three years in three teaching Hospitals in Addis Ababa, Ethiopia, i.e. Tikur Anbassa (TAH), Princess Zewditu Memorial (ZMH) and St. Paul's Hospitals (SPH). RESULTS: A total of 25 patients were analyzed. Two peak ages of occurrence were identified i.e. the 2nd decade, which represented mainly idiopathic intussusception, and the 4th decade, which was mainly of secondary type. The median duration of illness was 144 hours with a range of 6-720 hours. The Ileo-colic type was identified in 14 (56%) of the cases. Fifteen (60%) cases were primary (Idiopathic). Benign conditions represented the majority (67%) of the identified lead points. Intra operative reduction was successful in only 6 (24%) of the cases, all of which were idiopathic. Four of our patients died giving an overall mortality rate of 16%. All of the deaths were from the idiopathic variety. Irreversible septic shock with multi organ failure was the cause of death. CONCLUSION: Intussusception is not a rare disease in Ethiopian adults, the primary idiopathic variant occurring with a higher frequency. Identified lead points are usually benign, especially if they are situated in the small intestine. En-block resection of the involved intestinal segment should be the rule if there is an obvious ischemic change and limited resection is recommended if a lead point is identified.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号